Skip to content

Tempus AI and the High Cost of Data Alchemy




If you are a healthcare company in 2026, you really want to be an AI company. It adds a certain luster to the balance sheet that simple blood tests or diagnostic reports just cannot provide. Tempus AI, Inc. (TEM) has mastered this nomenclature, positioning itself as the bridge between the messy reality of oncology wards and the clean, high-multiple world of multimodal data.

Today, Wednesday, November 18, 2026, the company filed an SEC Form 8-K regarding a material definitive agreement. While the filing confirms the continuation of its operational momentum, it also highlights the central tension in the Tempus story: the business is growing its footprint in the lab, but it is still struggling to find the exit door from its own cash burn.

The market currently values Tempus AI at approximately $11.4 billion, a figure that reflects a massive premium for its “data-as-a-service” potential. However, the fundamental reality is that the company is currently a Health Information Services provider with a -1.32% free cash flow yield and a stock price of $62.37 that seems to be pricing in a level of profitability that the income statement has yet to encounter.

Tempus AI, Inc. (TEM) Financial Overview
Figure 1: Tempus AI, Inc. (TEM) Quarterly Financial Trajectory. Source: SEC EDGAR Filings & Market Data.

The Revenue Recognition and Collection Friction

The bull case for Tempus AI rests on the idea that every diagnostic test they run creates a permanent, valuable data asset that can be licensed to pharmaceutical giants. This is a beautiful narrative, but the accounting suggests some friction in the plumbing. Our forensic desk flagged an elevated concern: accounts receivable (AR) growth is currently outstripping revenue growth by more than 15%.

In plain English, this means the company is booking sales faster than it is collecting actual cash from its customers. When receivables bloat while operating cash flow remains negative, it often signals that the “high-margin” data licensing revenue might be subject to longer payment terms or more complex collection hurdles than the market realizes.

The company reported $411.5 million in revenue for the third quarter of 2026, which is an impressive headline number. CEO Eric Lefkofsky noted that the results reinforce the “durability of our model.” Yet, the company is still reporting a GAAP net loss, and the real free cash flow, when you strip out the $120 million in stock-based compensation, is a negative $280 million.

Capital Intensity and the AI Premium Gap

Tempus AI is currently trading at a Price-to-Book (P/B) ratio of 22.69x. To put that in perspective, many traditional healthcare service providers trade at single-digit multiples of book value. Investors are paying this premium because they believe Tempus is a software-style compounder rather than a capital-intensive laboratory business.

However, the historical trajectory shows that growth is expensive. In FY2024, the company saw an operating margin of -99.7%, which improved to -19.9% by FY2025. While the direction is correct, the absolute levels are still a long way from the “Rule of 40” benchmark that institutional investors use to identify healthy growth companies. Tempus currently scores a 13.1% on this metric, well below the 25% hurdle usually required to justify such an aggressive valuation.

Company (Ticker) Market Cap Forward P/E EV/EBITDA Rev Growth (YoY) Operating Margin FCF Yield
Tempus AI (TEM) $11.4B N/A N/A 23.10% -18.47% -1.32%
Eli Lilly and Company (LLY) $1.24T 27.3x 28.1x 38.6% 51.3% 0.76%
UnitedHealth Group (UNH) $321.8B 15.4x 13.9x -0.4% 5.9% 8.24%
Johnson & Johnson (JNJ) $665.8B 23.8x 26.6% 5.9% 26.6% 2.78%

When we look at the peer group, the valuation gap becomes even more stark. Eli Lilly (LLY) is growing revenue at nearly 39% with a 51.3% operating margin, yet Tempus AI commands a higher premium on several forward-looking growth metrics despite its negative margins. The market is treating Tempus as an unconstrained AI play, but its business model still requires physical lab throughput and significant research and development spend.

Options Structure and the Gravity of Max Pain

The options market is currently signaling a state of relative balance, but with a notable magnetic pull toward lower prices. The Put/Call open interest ratio stands at 1.06, suggesting that institutional hedgers are reasonably well-protected. However, the Max Pain strike sits at $70.00, which is about 12% above the current spot price of $62.37.

Max Pain is the price level where the largest number of options contracts expire worthless, often acting as a magnet for the stock as market makers hedge their positions. While this might suggest some upside potential into expiration, the primary call resistance (or “Call Wall“) at $80.00 represents a formidable ceiling. Dealers are incentivized to sell into rallies toward that level to maintain their delta-neutral hedges.

With an implied volatility of 81.71%, the market expects a massive 23.43% move in either direction over the next 30 days. For a company with $0.79 billion in net debt and a -37.55% return on equity, that volatility is a double-edged sword. If the market begins to sour on the “AI healthcare” narrative, the lack of fundamental valuation support could lead to a rapid re-pricing.

The Institutional Verdict

The core issue with Tempus AI is not that its technology is failing, but that its valuation has outpaced its economic reality. The company is successfully signing material agreements and growing its oncology unit by 32%, but it is doing so while burning through cash and relying heavily on stock-based compensation to keep the reported figures palatable.

The divergence between revenue growth and accounts receivable is a specific red flag that institutional investors should not ignore. It suggests that the quality of earnings is deteriorating just as the stock price is reaching for the stars. In an environment where the 10-Year Treasury yield is hovering around 5.07%, a company with a negative real free cash flow yield of -2.42% (after adjusting for SBC) is a difficult asset to hold.

Investment Committee Steelman Dissent: The strongest bull case for Tempus AI is that its multimodal data library is becoming an essential infrastructure for the next generation of personalized oncology, making it a prime acquisition target for a legacy pharmaceutical giant like Eli Lilly or Johnson & Johnson. If a suitor decides that the data library is worth more than the current cash-burning operations, a sudden M&A premium could override our fundamental sell thesis.

AllWallSt Investment Verdict: SELL (Initiation)

Institutional Audit • Healthcare

Tempus AI, Inc. (TEM)

Tier 4: Speculative / High Volatility • 0-6 Mos • 0.0% Allocation (Capital Preservation / Avoid) | Tactical Put Hedge < 0.5%
Market Data As Of: Nov 18, 2026 12:03 PM EST • 10-K Filed 2026-02-24 &bull; 10-Q Filed 2026-11-02 • Methodology

SELL
Independent Conviction

UNCONSTRAINED
Benchmark Gravity (Minimal Gravity)

Valuation & Yield
N/A
Trailing P/E
Forward P/E:-1577.0x
EV / EBITDA:-61.8x
FCF Yield:-1.32%
10Y Spread:-6.39% vs 10Y

Forensic Accounting
2 Flags
Marcus Wolfe Screen
Cash Conversion:N/A (GAAP Loss)
Accrual Ratio:-1.18%
Anomaly Risk:Elevated Risk
Earnings Quality:Anomaly Watchlist

Solvency & Liquidity
Capital Audited
Leverage Profile
Net Debt:$0.79B
Total Cash:$637.4M
Total Debt:$1.43B
CapEx Intensity:2.80%

Market Structure & Vol
$47.75 – $76.99
30D Channel
Max Pain Strike:$70.00 (+12.15%)
Put / Call OI:1.06
30D Implied Vol:81.71%
Gamma Wall Bounds:$50P / $80C



Dealer Gamma Pinning & Max Pain Alignment (TEM)
30D Implied Vol: 81.71% • Put/Call OI: 1.06


🎯 Max Pain: $70.00

▼ Floor $50P Support
Spot $62.37
Ceiling $80C Resistance ▲

Market Structure Verdict: Spot ($62.37) is trading 10.9% below Max Pain, creating upside pin pull into OPEX.
30D Expected Move: ±$14.62

Channel Guide: 🎯 Top Pin marks Max Pain magnet. Cyan Band spans Put Floor to Call Ceiling dealer walls (30D 1-Sigma Range: $47.75 – $76.99). White Cursor tracks live Spot price, framed between Emerald Put Floor (left) and Rose Call Ceiling (right).

Institutional Desk Takeaways & Execution Bounds
Forensic Screener:
ELEVATED CONCERN (2 flags): Operating cash flow is negative (-218,090,000) alongside GAAP net loss, signaling active cash burn. Receivables growth outstripped revenue growth by >15%, pointing to potential revenue recognition or collection friction.
Credit & Solvency:
Manageable liability structure relative to institutional cash flow.
Macro & Rates Impulse:
Negative yield spread (-6.39% vs 5.07% Treasury); equity requires robust multiple expansion or growth.
Options Market Structure:
Max Pain: $70.00 (+12.15%) | P/C Ratio: 1.06 | 30D Channel: $47.75 – $76.99. Dealer gamma bounded between $50 Put Wall and $80 Call Wall.
Benchmark Gravity:
TEM operates with negligible index gravitational pull. Sell-side ratings reflect pure idiosyncratic fundamental consensus without passive indexing distortion.

Distribution / Exit Zone:
$78.40 – $81.60 (Call Wall Resistance Distribution Ceiling)

Upside Invalidation (Short Break):
Sustained weekly close above $80.00 (Call Wall Resistance) or structural rebound in GAAP Free Cash Flow.

IC Steelman Dissent:
Bullish IC Dissent: Despite current valuation multiples and -1.32% FCF yield alongside 2 flagged accrual anomalies, Tempus AI, Inc. (TEM) could stage a sharp short-covering squeeze if management surprises with cost discipline, buyback acceleration, or stabilizing guidance above the $80 call wall. Consensus pessimism already prices in significant deterioration, creating asymmetric upside risk if credit spreads remain contained.

Governance: Institutional ratings, risk tier suitability, and execution bounds generated algorithmically by the AllWallSt Autonomous Multi-Agent Research Architecture (Valuation Desk ‘Alexander Sterling’, Forensic Accounting Desk ‘Marcus Wolfe’, Quantitative Risk Desk, and Macro Strategy Desk). Independent Conviction reflects unconstrained fundamental cash flow and forensic accounting scrutiny; Benchmark Gravity reflects passive index tracking mandates and Wall Street sell-side career-risk pressures. Quantitative inputs audited directly from primary SEC EDGAR regulatory filings and official market exchange records. Full scoring formulas and risk tiers: AllWallSt Quantitative Methodology.

Institutional Compliance & AI Research Disclosure: AllWallSt is a quantitative financial publishing and algorithmic research platform, not a registered investment adviser, broker-dealer, or FINRA member. Named analytical desks and personas (including Alexander Sterling and Marcus Wolfe) represent specialized algorithmic agents within an autonomous multi-agent research architecture, not licensed human analysts. All content, financial metrics, and execution levels are provided exclusively for institutional research, financial education, and general market analysis, and do not constitute personalized investment advice, a recommendation, or an offer to buy or sell any security. Historical financial performance and quantitative model bounds do not guarantee future market outcomes. Always consult a licensed fiduciary financial advisor before making investment decisions.

Sources & References


Disclaimer: AllWallSt provides financial analysis and reporting for informational purposes only. This report does not constitute investment advice, a recommendation, or an offer of any security. Investing involves significant risk, and past performance is not indicative of future results. Consult with a qualified financial advisor before making any investment decisions.